![](https://static.youtibao.com/asksite/comm/h5/images/m_q_title.png)
[单选题]
2018年ASCO公布的卡瑞利珠单抗联合阿帕替尼治疗晚期NSCLC的Ib期研究中,总体的ORR是?()
A.30.8%
B.49.1%
C.41.2%
D.39.1%
查看答案
![](https://static.youtibao.com/asksite/comm/h5/images/solist_ts.png)
A.30.8%
B.49.1%
C.41.2%
D.39.1%
A.39%
B.40%
C.41%
D.42%
A.22%
B.43.2%
C.77.3%
D.9.5%
A.纳武利尤单抗PFS,OS均无获益
B.阿替利珠单抗PFS,OS均无获益
C.阿帕替尼联合卡瑞利珠单抗,中位PFS为3.6m,中位OS为8.4m
D.安罗替尼联合伊立替康/多西他赛,ORR达33.3%,中位PFS达4.0m
A.74.1%
B.22%
C.9.3%
D.15.9%
A.卡瑞利珠单抗+阿帕替尼,Q2W
B.卡瑞利珠单抗+卡铂+培美曲塞,Q2W
C.卡瑞利珠单抗+顺铂+培美曲塞,Q3W
D.卡瑞利珠单抗+卡铂+培美曲塞,Q3W